"Data is the key. The depth of biological data, the depth of demographical data, the depth of epidemiological data has to be properly collected,"
"Screening usually happens when people get older. But what we are trying to do-all of us sitting here-is understand the biology of aging so that we can intervene as early as possible,"
"We're looking for protein targets and drugs that may work on a disease and work on aging at same time,"
AI technology is poised to accelerate longevity and healthspan research, but insufficient, noncomprehensive data limits progress. Biological, demographic, and epidemiological datasets require broader and deeper collection to capture how cells and organs age across genders, ethnicities, and environments. Current healthcare systems tend to screen for aging late in life, while aging processes begin much earlier. Collaborative efforts between nonprofits, scientists, and biotech aim to speed drug discovery focused on reducing age-related diseases and improving consumer access. AI-driven programs prioritize dual-purpose targets that may treat specific diseases and simultaneously affect aging mechanisms.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]